HDACs class I, II, IV mutations in human cancer

Slides:

Advertisements

Similar presentations

THE GENETIC OF CANCER Increased mitosisTumor formation Tumor suppression gene Hyperactive growth TranslocationPoint mutationAmplification Normal growth.

Advertisements

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.

Progress in Cancer Therapy Following Developments in Biopharma

Ramucirumab Protein chemical formula : C6374H9864N1692O1996S46

Schema for a human microbiome study

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

T-Cell Exhaustion: Can We Overcome It in Cancer?

Inhibitor of MAP kinase activation blocks colon cancer growth

Advances in Specific Immunotherapy for Prostate Cancer

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients.

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The PI3K/Akt signalling and its activation in cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The hallmarks of adenovirus infection

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Schematic diagram of antibody drug conjugate

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 6 Combination therapy for HCC

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

Minyoung Her, MD, Arthur Kavanaugh, MD

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

(A) An overview of the JAK/STAT signalling pathway.

Molecular approaches to HER2 targeted therapy

An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal.

Targeted Therapies in Melanoma: Translational Research at Its Finest

ADVANCED TARGETING SYSTEMS for specific elimination of cell types

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Model of the function of TBX2 in RMS.

Figure 2 from Sancho et al.

The cancer stem cell concept in cancer progression and metastasis

The putative genomic evolution of prostate cancer from normal epithelium to castrate-resistant, metastatic cancer Figure 2 from Mitchell and Neal British.

Figure 1 from B Zhu British Journal of Cancer (2015) 112, ; doi: /bjc

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

Lipid Soluble Hormone.

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

A hypothetical scheme targeting autophagy for glioblastoma sensitisation during radio-chemotherapy with TMZ Figure 1 from Michael I Achilleas G and.

Figure 2 Site of action of checkpoint inhibitors and agonists being

Nat. Rev. Urol. doi: /nrurol

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Figure 1 from M Holderfield

Molecular features of the colon during homeostasis and carcinogenesis

Figure 1 from T Schenk et al.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Fbxw7 ablation in LICs for CML sensitises the cells to imatinib by preventing quiescence. Figure 2 from S Takeishi British Journal of Cancer (2014) 111,

Translating Germline Cancer Risk into Precision Prevention

In melanoma tumours expressing the BRAFV600E oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.

Figure 1 Mechanisms of action of immunotherapy modalities

Mitochondrial priming model

Nat. Rev. Cardiol. doi: /nrcardio

Spectrum of cellular processes regulated by AXL activity

Figure 1 from D’Incalci et al.

Involvement of actin cytoskeletal reorganisation in EMT

The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc

Target antigens for ADCs in solid tumours

Macrophage differentiation and their role in tumourigenesis

Model of EphA/ephrin-A expression in GBM.

by Jennifer Couzin-Frankel

Presentation transcript:

HDACs class I, II, IV mutations in human cancer Figure 1 from Ceccacci and Minucci British Journal of Cancer Advance Online Publication 23 February 2016 doi:10.1038/bjc.2016.36 Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2016 Cancer Research UK.